Patent: 10,259,877
✉ Email this page to a colleague
Summary for Patent: 10,259,877
| Title: | Methods for treating or preventing migraine headache |
| Abstract: | The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described. |
| Inventor(s): | Sun Hong, Dunayevich Eduardo, Lenz Robert A., Vargas Gabriel |
| Assignee: | AMGEN INC. |
| Application Number: | US15136736 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,259,877
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | AIMOVIG | erenumab-aooe | Injection | 761077 | May 17, 2018 | ⤷ Start Trial | 2036-04-22 |
| Amgen Inc. | AIMOVIG | erenumab-aooe | Injection | 761077 | March 11, 2019 | ⤷ Start Trial | 2036-04-22 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,259,877
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 201707179 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2016171742 | ⤷ Start Trial |
| United States of America | 11466090 | ⤷ Start Trial |
| United States of America | 2016311913 | ⤷ Start Trial |
| United States of America | 2019256607 | ⤷ Start Trial |
| United States of America | 2023020514 | ⤷ Start Trial |
| Taiwan | 201637667 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
